Clinical Trial Detail

NCT ID NCT03633110
Title Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genocea Biosciences, Inc.
Indications

renal cell carcinoma

transitional cell carcinoma

head and neck squamous cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

GEN-009

GEN-009 + Nivolumab

Age Groups: senior adult

No variant requirements are available.